Search our team at AdventHealth Research Institute
-
NCT05840211
A Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients with Hormone Receptor-Positive (HR+)/Human Epidermal Growth Factor Receptor 2-Negative (HER2−) (HER2 IHC0 or HER2-low [IHC 1+, IHC 2+/ISH−]) Inoperable, Locally Advanced, or Metastatic Breast Cancer and Have Received Endocrine Therapy ASCENT 07
This study is not currently enrolling.Associated Conditions: Breast CancerResearch Area: Cancer ResearchResearch Location: Altamonte, FloridaThe purpose of this study is to see if sacituzumab govitecan can improve life spans of patients with HR+/HER2- metastatic breast cancer and their tumor does not grow or spread when compared to current...
-
NCT05514054
EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence
This study is not currently enrolling.Associated Conditions: Breast CancerResearch Area: Cancer ResearchResearch Location: Altamonte, FloridaThis study is being done to see how safe an investigational drug is and how well it will work to help people with Estrogen receptor positive (ER+), human epidermal growth factor receptor 2-negative...
-
NCT05047263
FIND-CKD: A randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase 3 study to investigate the efficacy and safety of FInerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease.
This study is not currently enrolling.Research Area: Translational ResearchResearch Location: Orlando, FloridaStudy Purpose: To determine the safety and efficacy of Finerenone along with standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease.
To be...
-
NCT05626634
A Phase 2, multicenter, open-label, long-term safety study of LP352 in subjects with developmental and epileptic encephalopathy who completed Study LP352-201 and are candidates for continuous treatment for up to 52 weeks.
This study is not currently enrolling.Research Area: Neuroscience ResearchYou, or you and the individual you care for, are being asked to take part in a research study because you have seizures associated with developmental and epileptic encephalopathy (DEE) and you have...
-
NCT05662865
CASINO: Low-Carbohydrate Diet and SGLT2-Inhibitor to Achieve Moderate Ketosis in Healthy Volunteers
This study is not currently enrolling.Research Area: Translational ResearchResearch Location: Orlando, FloridaThe purpose of this study is to test the hypothesis that a low-carbohydrate diet combined with an SGLT2-inhibitor is sufficient to induce moderate ketosis in healthy volunteers.
To be enrolled in...
-
NCT04865770
REMODEL: Renal Mode of Action of Semaglutide in Patients with Type 2 Diabetes and Chronic Kidney Disease.
This study is not currently enrolling.Associated Conditions: Diabetes-Care DeliveryResearch Area: Translational ResearchResearch Location: Orlando, FloridaStudy Purpose: The purpose of this study is to determine how Semaglutide works in the kidneys in people with type 2 diabetes and chronic kidney disease.
To be enrolled in this study, you must meet...
-
NCT05394519
REDEFINE2: Efficacy and safety of cagrilintide s.c. 2.4 mg in combination with semaglutide s.c. 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) once-weekly in participants with overweight or obesity and type 2 diabetes.
This study is not currently enrolling.Associated Conditions: Diabetes-Drug StudyResearch Area: Translational ResearchResearch Location: Orlando, FloridaStudy Purpose: The purpose of the study is to investigate the efficacy and safety of two medications, cagrilintide and semaglutide. Cagrilintide in combination with semaglutide is currently under...
-
NCT04529772
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R CHOP) in Subjects ≤70 Years with Previously Untreated Non-Germinal Center Diffuse Large B Cell Lymphoma
This study is not currently enrolling.Associated Conditions: LeukemiaResearch Area: Cancer ResearchResearch Location: Orlando, FloridaThis study is being done to understand whether patients with a type of DLBCL known as non-germinal center diffuse large B-cell lymphoma (non-GCB DLBCL) will benefit from the addition of acalabrutinib...
-
Donor Breast Milk and Serum Ferritin Levels in Very Preterm Infants: A Prospective, Observational Study
This study is not currently enrolling.Associated Conditions: NeonatalResearch Area: Pediatrics ResearchResearch Location: Orlando, FloridaThe purpose of the study is to compare the iron levels in very preterm infants receiving donor breast milk (DBM) to very preterm infants receiving maternal breast milks (MBM).
-
NCT03000439
You are being asked to take part in this research study because you have Systemic Juvenile Idiopathic Arthritis (sJIA) which may cause joint swelling and pain, fever, or other symptoms affecting the whole body (such as rash, swelling of your lymph nodes, a large liver or spleen, or inflammation of the lining around your lungs or heart). The purpose of this research study is to compare the effectiveness of the study drug, tofacitinib, to placebo for treatment of signs and symptoms of sJIA.
This study is not currently enrolling.Associated Conditions: Immunology/RheumatologistResearch Area: Cancer ResearchResearch Location: Orlando, FloridaYou are being asked to take part in this research study because you have Systemic Juvenile Idiopathic Arthritis (sJIA) which may cause joint swelling and pain, fever, or other symptoms affecting the...
-
NCT03683186
ADVANCE EXTENSION - A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects with PAH via an Open-Label Extension
This study is not currently enrolling.Research Area: Heart, Lung and Vascular ResearchIf you have taken part in a research study with ralinepag, the investigational study drug, you may be able to take part in this extension study. This means that all participants will receive the...
-
NCT04537377
A Phase I/II, Multicenter, Non-randomized, Open Label, Adaptive Design, 5-year Follow up, Single Dose-escalation Study of VTX-801 in Adult Patients with Wilson’s Disease.
This study is not currently enrolling.Associated Conditions: Wilsons DiseaseResearch Area: Cancer ResearchResearch Location: Orlando, FloridaThis Clinical Trial is being conducted to assess the effects of an experimental drug (study drug) called VTX-801 intended to treat Wilson’s Disease (WD). The purpose of this clinical study is to...